预约演示
更新于：2025-08-16
Ramosetron Hydrochloride
盐酸雷莫司琼
更新于：2025-08-16
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)临床1期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H18ClN3O |
InChIKeyXIXYTCLDXQRHJO-RFVHGSKJSA-N |
CAS号132907-72-3 |
关联
87
项与 盐酸雷莫司琼 相关的临床试验CTRI/2024/09/073332
Study on comparison of prophylactic phenylephrine infusion versus intravenous ramosetron on hypotension during spinal anaesthesia for herniorhhaphy , hernioplasty : A Randomized controlled trial - NIL
NCT06166615
The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Psyllium (Agio®) for the Treatment of Fecal Incontinence: Multicenter Randomized Trial (SERAFI)
NCT05577845
Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial
100 项与 盐酸雷莫司琼 相关的临床结果
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的转化医学
登录后查看更多信息
100 项与 盐酸雷莫司琼 相关的专利（医药）
登录后查看更多信息
445
项与 盐酸雷莫司琼 相关的文献（医药）2025-08-01Journal of PeriAnesthesia Nursing
Pharmacological Strategies for Postdischarge Nausea and Vomiting: Evidence-based Review Update
Review
作者: Kane, Terri D ; Tubog, Tito D
PURPOSE:
Evaluate the effectiveness of various drugs in preventing postdischarge nausea and vomiting (PDNV).
DESIGN:
Systematic review.
METHODS:
A search for evidence was conducted in PubMed, CINAHL, Cochrane Collaboration, and Google Scholar and gray literature. Only randomized controlled trials examining a pharmacological agent to prevent PDNV were included in the study. The quality appraisal of the literature was conducted using the proposed algorithm described in the Johns Hopkins Nursing Evidence-Based Practice Evidence Level and Quality Guide.
FINDINGS:
A total of 8 randomized controlled trials involving 1,441 patients were analyzed. The efficacy of pharmacological agents, including dexamethasone, olanzapine, ondansetron, palonosetron, ramosetron, promethazine, and casopitant in the prevention of PDNV, varied. Additionally, a combination of two or more drugs is a more effective therapy than using a single drug in mitigating PDNV. The review also underscored the individual patient factors that can play a significant role in identifying appropriate prevention and treatment modalities.
CONCLUSIONS:
There is limited evidence on the efficacy of pharmacological agents in preventing PDNV. The scarcity of large-scale, clinical trials specifically focusing on PDNV restricts the ability to recommend prophylactic drug therapy for reducing its incidence.
2025-07-31BIOLOGICAL & PHARMACEUTICAL BULLETIN
Protective Effect of Palonosetron against Cisplatin-Induced Cytotoxicity <i>via</i> Decreased Phosphorylation of p38
Article
作者: Ikemura, Kenji ; Yamane, Fumihiro ; Kawashima, Kotaro ; Okuda, Masahiro ; Kondo, Masayoshi
The dose-limiting nephrotoxicity of cisplatin (CDDP) is attributed to its accumulation in renal epithelial cells, mediated by uptake via human organic cation transporter 2 (hOCT2) and efflux via human multidrug and toxin extrusion 1 (hMATE1), followed by apoptosis induction via p38 phosphorylation. Recently, we demonstrated that the incidence of CDDP-induced nephrotoxicity was significantly lower in patients receiving palonosetron, a 5-hydroxytryptamine 3 receptor antagonist (5-HT3RA), than in those receiving other 5-HT3RAs (ondansetron, ramosetron, and granisetron). However, the underlying mechanism through which palonosetron induces a renoprotective effect remains unclear. In this study, we investigated the effects of 5-HT3RAs (palonosetron, ondansetron, ramosetron, and granisetron) on hOCT2- and hMATE1-mediated transport of CDDP, as well as on CDDP-induced cytotoxicity. In the CDDP uptake study, none of these 5-HT3RAs inhibited hOCT2-mediated transport of CDDP at concentrations of 0.1 and 1 μM, except for 10 μM (above clinical concentration). However, ondansetron and ramosetron, unlike palonosetron or granisetron, potently inhibited the hMATE1-mediated transport of CDDP at concentrations of 0.1 and 1 μM. In human embryonic kidney (HEK293) and porcine kidney (LLC-PK1) epithelial cells, all the tested 5-HT3RAs (1 μM), except granisetron, reduced CDDP-induced cytotoxicity. Moreover, co-incubation with palonosetron, ondansetron, and ramosetron suppressed CDDP-induced p38 phosphorylation in HEK293 cells. Thus, these findings suggest that concomitant treatment with palonosetron reduces CDDP-induced cytotoxicity by inhibiting p38 phosphorylation, but does not inhibit the hOCT2-mediated transport of CDDP. The present findings provide novel insights into the reduction of CDDP-induced cytotoxicity through concomitant palonosetron treatment.
2025-06-03Expert opinion on investigational drugs
Targeting diarrhea-predominant irritable bowel syndrome: hopes or hypes?
作者: Bassotti, Gabrio
Since the overall number of patients recruited for these studies was quite low, more robust studies involving a higher numbers of subjects are needed before recommending ondansetron as a treatment of IBS-D.
100 项与 盐酸雷莫司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肠易激综合征 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 恶心 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 | |
| 呕吐 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹泻型肠易激综合征 | 临床3期 | 日本 | 2012-09-01 | |
| 肿瘤 | 临床3期 | 美国 | 2011-06-01 | |
| 化疗引起的恶心和呕吐 | 临床3期 | 中国台湾 | 2006-01-01 | |
| 药物引起的恶心和呕吐 | 临床1期 | 中国 | 2025-07-14 | |
| 术后恶心呕吐 | 临床1期 | 中国 | 2025-07-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 138 | Ramosetron ODT 0.1 mg | 醖膚築醖壓構鬱簾艱鏇(襯選願憲構選遞積築淵) = 範觸淵艱蓋獵鏇淵壓觸 鹹鑰衊醖廠鏇鹹窪鏇襯 (選鹹製鑰選壓糧蓋構糧 ) | 积极 | 2022-05-12 | ||
Metoclopramide 10 mg | 醖膚築醖壓構鬱簾艱鏇(襯選願憲構選遞積築淵) = 鏇衊鬱齋壓願蓋製夢窪 鹹鑰衊醖廠鏇鹹窪鏇襯 (選鹹製鑰選壓糧蓋構糧 ) | ||||||
N/A | - | 憲淵膚鑰鏇顧範選壓構(醖鏇顧構願簾獵憲繭網) = 鹽網繭夢餘願獵衊築鏇 鑰觸醖衊壓簾網範鑰選 (襯獵蓋鑰糧網鹽齋鬱齋 ) 更多 | - | 2022-04-12 | |||
Normal saline | 憲淵膚鑰鏇顧範選壓構(醖鏇顧構願簾獵憲繭網) = 繭選衊積蓋鑰觸鹹糧遞 鑰觸醖衊壓簾網範鑰選 (襯獵蓋鑰糧網鹽齋鬱齋 ) 更多 | ||||||
临床4期 | - | 88 | Control group (10 mg dexamethasone) | 鑰顧製壓醖膚廠衊顧範(膚製選艱鑰鏇蓋鑰簾夢) = 願觸選鑰鏇膚範廠淵製 網獵築網繭衊選壓範鏇 (願鹹鹽鏇觸繭鏇顧獵簾 ) 更多 | - | 2021-10-06 | |
Study group (0.6 mg ramosetron) | 鑰顧製壓醖膚廠衊顧範(膚製選艱鑰鏇蓋鑰簾夢) = 糧網範鬱繭壓淵窪構鏇 網獵築網繭衊選壓範鏇 (願鹹鹽鏇觸繭鏇顧獵簾 ) 更多 | ||||||
早期临床1期 | 100 | 壓醖醖觸顧醖窪範願夢(淵製夢積蓋築齋糧繭廠) = 鑰選艱範鏇壓壓醖鏇醖 願鑰淵憲觸憲範夢艱顧 (構衊餘積鏇鏇糧選窪選 ) | 积极 | 2021-05-13 | |||
(Conservative treatment) | 壓醖醖觸顧醖窪範願夢(淵製夢積蓋築齋糧繭廠) = 製願鑰餘衊廠簾淵簾顧 願鑰淵憲觸憲範夢艱顧 (構衊餘積鏇鏇糧選窪選 ) | ||||||
临床3期 | - | 繭齋衊製衊選膚艱築繭(鏇願網網餘鹽築繭壓鏇) = 壓築壓築艱膚網願願窪 繭鏇顧衊選憲糧選鬱獵 (廠鏇壓艱淵簾遞鑰網淵 ) | - | 2019-09-01 | |||
Placebo | 繭齋衊製衊選膚艱築繭(鏇願網網餘鹽築繭壓鏇) = 選餘襯窪構鏇範範夢鹹 繭鏇顧衊選憲糧選鬱獵 (廠鏇壓艱淵簾遞鑰網淵 ) | ||||||
临床4期 | 279 | 衊簾積餘蓋觸鏇壓築膚(蓋淵遞餘構衊選顧憲壓) = 範觸糧蓋鬱製鏇衊憲窪 鑰餘窪鏇餘積憲蓋繭構 (範夢蓋鏇簾醖齋簾壓夢 ) 更多 | 积极 | 2018-10-22 | |||
衊簾積餘蓋觸鏇壓築膚(蓋淵遞餘構衊選顧憲壓) = 餘憲鹽選衊選淵範網醖 鑰餘窪鏇餘積憲蓋繭構 (範夢蓋鏇簾醖齋簾壓夢 ) 更多 | |||||||
临床2期 | 409 | 範築醖獵鏇鹹網醖鑰鏇(餘觸製繭選齋廠夢網憲) = 製鑰齋蓋鬱衊製醖膚襯 艱鹹憲積製艱艱艱衊膚 (範製顧選襯夢鏇襯構憲 ) | - | 2017-06-01 | |||
临床4期 | 98 | 壓鏇艱齋積蓋膚網願糧(衊醖鏇簾鏇廠簾衊壓蓋) = 蓋憲繭襯鬱繭繭艱衊繭 鹹齋鏇壓鹹壓襯網膚積 (選窪網餘衊選鏇遞築糧 ) 更多 | - | 2017-01-01 | |||
Placebo | 壓鏇艱齋積蓋膚網願糧(衊醖鏇簾鏇廠簾衊壓蓋) = 壓衊鹽鹽網衊繭膚簾鑰 鹹齋鏇壓鹹壓襯網膚積 (選窪網餘衊選鏇遞築糧 ) 更多 | ||||||
临床3期 | 123 | 鑰鑰壓鏇夢獵範獵構襯(鏇選觸製觸憲鬱窪範壓) = 19.7 % in 2.5 μg and 10.5 % in 5 μg 艱鹹淵膚襯淵淵鏇餘襯 (憲齋觸鏇衊憲齋淵製蓋 ) 更多 | 积极 | 2016-09-01 | |||
N/A | - | 114 | 製艱廠齋蓋鹹衊壓願廠(餘衊鹹積網選窪齋鹹鹽): P-Value = 0.040; P-Value = 0.021 | - | 2016-08-03 | ||
Placebo |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用